A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome

A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and safety and tolerability of in-hospital initiation of

Benefits of Microcor (uCorTM) in Ambulatory Decompensated Heart Failure

PULSAR VASCULAR PulseRider? Aneurysm Neck Reconstruction Device HDE Holder Information: Pulsar Vascular, Inc. 130 Knowles Drive, Suite ELos Gatos, CA 95032 USA

STERLING REGISTRY – A Prospective, Multi-Center, Single Arm, Study to obtain ?real world? clinical data and characterize the acute & long term performance of the Micrusframe & Galaxy Coils for the Endovascular treatment of Intracranial […]

Proximal Inter Phalangeal Finger Joint Prosthesis

Tracking Results of Ablations to Combat AF Registry (Formerly the Maze IV Registry)

A phase 2, multicenter, randomized, double-blind, placebo-controlled study of naldemedine in patients undergoing surgeries that include a bowel resection or bowel transection

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axilla

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR?S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER S

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A,), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER S

A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer (New Adjuvant TriAl with Ri

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal

Evaluation of Biomarkers as a Predictor of Cancer and Healing

An Evaluation of Childhood Overweight and Obesity Screening and Management in the Primary Care Setting.

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial

Determining the Optimal Treatment Strategy for Patients who have Chronic Migraine with Medication Overuse (MOTS Trial – Medication Overuse Treatment Strategy)

A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir? System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease with Chronic Bronchitis (SPRAY-CB)

NCCTG N0577/Endorsed Study: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

AANS and ASTRO Stereotactic Radiosurgery Registry (SRS Registry)

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate system (LAANTERN) Prospective Registry

Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization

Convalescent Plasma in the Early Treatment of High-Risk Patients with SARS-CoV-2 (COVID-19) Infection

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

Prospective Blood and Tissue Sample Collections in Symptomatic and Asymptomatic Pregnant Women During the COVID-19 Pandemic Period

Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants with Respiratory Compromise

An Assessment of P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion with Instrumentation

A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)

A Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy

A Randomized, Placebo-Controlled, Double-Blind Study Of Adjuvant Cemiplimab Versus Placebo After Surgery And Radiation Therapy In Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 2 Study of INCMGA00012 in Patients with Metastatic Merkel Cell Carcinoma (POD1UM-201)

A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1

Effects of a Smartphone App on Compliance and Function in Patients with Breast Cancer

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Me

PANOVA 3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for frontline treatment of locally-advanced pancreatic adenocarcinoma

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic u

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

A Phase Ib/II Open Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma After Failure With Platinum-Con

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Mus

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Car

An Expanded/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) and Metastatic Castrate Resistant Prostate Cancer (mCRP

An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEY

Jostent GraftMaster Coronary Stent Graft & Delivery System for the treatement of free perforation, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts

Bone Graft Donor Site Pain after Cervical Spine Surgery

A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ov

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who have Previously Received PARP Inhibitor Maintenance Treatm

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator?s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or

A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-foot Skin Reaction in Cancer Patients

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) ? Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS […]

NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carc

Product Surveillance Registry / Site 10123001

Care Optimization through Patient and Hospital Engagement Clinical Trial for Heart Failure, CONNECT-HF trial

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton?s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Na?ve Subjects with Follicular Ly

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin?) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

A Randomized Phase 3 Study to Evaluate the efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Na?ve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1. (ENGINE Study)

A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.

A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to Lenalidomide

A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Pla

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

HbO2 Hemopure – HBOC-201 (IND# 18513)

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator?s Choice of Chemoimmunotherapy in Subjects with Previo

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.

Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (? 60 […]

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma

Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory […]

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Specimen Collection to Support Pre-Clinical and Clinical Validation Studies of the Xpert BCR-ABL p190 Ultra Test

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia

A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Specimen Collection to Support Analytical Validation Studies of the Xpert BCR-ABL p190 Ultra Test

A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ab

The Wingspan Stent System and Gateway PTA Balloon Catheter, a Humanitarian Use Device

Does Red Box Isolation Increase Adherence to Isolation Precautions and PPE Compliance?

A Humanitarian Device Exemption Treatment Protocol of TheraSphere? For Treatment of Unresectable Primary or Secondary Liver Neoplasia

A Concurrently Controlled Study of the LimiFlex? Paraspinous Tension Band in the Treatment of Lumbar Degenerative Spondylolisthesis with Spinal Stenosis

Impact of Dronabinol on Post-operative Pain After Lumbar Fusion for Degenerative Disorders of the Spine

A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inh

A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Adva

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

HUMANITARIAN USE DEVICE: The Spiration? Valve System Protocol# H060002

SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination with Nivolumab, an anti-PD-1 antibody, for Subjects with HER2-expressing Advanced Breast

A Phase 1 Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses and treatment intensification of a vaccine-based immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for advanced non-small cell lung cancer and metastatic tripl

An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 na?ve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had […]

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Metastatic Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Releva

A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Ce

An open-label, multi-center, phase 1b/2 study to evaluate the safety and efficacy of copanlisib in combination with nivolumab in patients with advanced solid tumors

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Collection And Distribution Of Biofluids And Tumor Tissue Biospecimens For Research Purposes

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors – ARTISTRY-1

TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial

An Observational Study Of Ocrelizumab-Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies (VERISMO STUDY)

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Registry To Evaluate Effectiveness And Safety Of The NanoKnife System For The Ablation Of Stage 3 Pancreatic Adenocarcinoma: The Direct Registry For IRE Cancer Treatment

A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife? System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients

Antithrombin III (AT) Activity in Women with Severe Preeclampsia (PE) or Superimposed PE prior to 31 weeks

Clinical Evaluation of the Xpert Xpress GBS Test

SR? MCP Implant System ~ Metacarpophalangeal Finger Joint Prosthesis

Vertical Expandable Prosthetic Titanium Rib (VEPTR)

Scoliosis-Specific Exercises for At-Risk Mild AIS Curves: A Multi-Site Preliminary Randomized Trial

Rasch Analysis of the Scoliosis Research Society?22R Instrument in Adults

A Multicenter Prospective Study of Quality of Life in Adult Scoliosis (Long-term Follow-Up)

Quantitative Romberg Test in Normal Healthy Volunteers and Patients with Spinal Deformity

Balance Variations in DIERS Pedoscan measurements

Prospective, Multi?Center Adult Spinal Deformity Outcomes Database Registry

Improving Efficiency of Robotic?Assisted Spine Surgery

Spinal Laminectomy versus Instrumented Pedicle Screw II Study (SLIP II)

Embotrap eXtraction & Clot EvaLuation & Lesion Evaluation for NeuroThrombectomy – EXCELLENT

Stopping fish oil supplementation prior to total hip replacement a randomized clinical trial

Randomized Clinical Trial of Exparel vs Pain Pump for Post-operative Pain Control after Total Shoulder Arthroplasty

National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases / Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

Cordis Enterprise Vascular Reconstruction Device and Delivery System